The technology includes CG0070, a replication – deficient adenovirus has successfully completed a Phase I clinical trial for the treatment of superficial bladder cancer. In return for the technology, BioSante received a 19.9 % share position in the Cold Genesys and a $ 95,000 cash payment in advance and authorized to future milestone payments and royalties.. GSK says it has more than 20 potential blockbusters in development .Various drugs have very different success rates in the treatment of patients, the majority of drugs. Have an efficacy of 50 percent .It is generally in the scientific and medical community that more research in genetic engineering is essential agreed.BioSante Pharmaceuticals Sells Oncolytic Virus Technology to Cold Genesys,BioSante Pharmaceuticals, Inc.
Explained that currently explained that currently pharmaceutical companies to adopt ‘one – drug-fits-all ‘policy.
Paul A. DeRidder, urologist and COO Genesys Cold states, ‘CG0070 showed that the destruction of tumor cells by direct adenovirus-mediated oncolysis and GM-CSF induced anti – tumor cell immune activation can be achieved because of the significant. Toxicity and limited efficacy of current treatment options will required additional therapies for superficial and invasive bladder cancer, to increase bladder preservation and long-term results.Parental and young consulter to to call FRANK at faith 0800 77 66 00 or go to resource materials from the FRANK campaign Hotline For 870-155-5455, or drugs.uk from the site / campaign available to.
2 For additional information about the report in: Mary Field-Smith, VSA Mortality Study, Division of Community Health Sciences, University of London: 020 8725 0843, Fax: 44-208-725-3584, e-mail: and John Ramsey, Director of the TICTAC Communications Ltd., University of London believe: 44-208-672-1006/44-208-725-5883/07774 the 138th Fax: 44-208-725-5892, e-mail:. Emma Griffiths 44-208-725-1139 St. George’s University of London in sgul..